SRRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's lead product, apitegromab, has significant blockbuster potential, nearing FDA approval with a de-risked manufacturing process. Analysts are bullish with consistent Buy ratings and price targets significantly above the current price. While technical indicators are neutral, the long-term growth potential and market share dominance for apitegromab make this a strong investment opportunity.
The MACD is negatively expanding (-0.323), suggesting bearish momentum. RSI is neutral at 37.258, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 46.89), with resistance at R1: 50.518. Overall, technical indicators are neutral.
Apitegromab nearing FDA approval with a de-risked manufacturing process.
Analysts project multi-billion dollar sales potential for apitegromab.
Competitor Roche has exited the market, leaving Scholar Rock with near-complete market share in SMA muscle-building therapy.
Analysts consistently rate the stock as a Buy with price targets ranging from $57 to $70, significantly above the current price.
Technical indicators are neutral, with no clear upward momentum.
Financial performance shows negative net income (-$90.97M) and EPS (-0.75), though improving YoY.
In Q4 2025, revenue remained at $0. Net income improved by 36.88% YoY to -$90.97M, and EPS increased by 22.95% YoY to -0.75. Gross margin remained at 0%. While financials are improving, the company is not yet profitable.
Analysts are overwhelmingly bullish on SRRK, with consistent Buy ratings and price targets ranging from $57 to $70. Recent updates highlight apitegromab's strong approval prospects and commercial potential, with a late-2026 launch expected. Analysts view the manufacturing resubmission as a material de-risking event.
